Nikolaus F. Rentschler and Frank Mathias Awarded as "EY Entrepreneur of the Year"

Nikolaus F. Rentschler and Frank Mathias have been awarded as EY Entrepreneur...
Nikolaus F. Rentschler and Frank Mathias have been awarded as "EY Entrepreneur of the Year" in the category "Industry." © tomertu/Shutterstock

Rentschler Biopharma’s chairman of the board, Nikolaus F. Rentschler, together with CEO Frank Mathias have received the "EY Entrepreneur of the Year" award 2019 in the category "Industry". The award, initiated by Ernst & Young, was presented in Stuttgart, Germany on Oct. 25, 2019 to German entrepreneurs, chosen by an independent jury from among 38 finalists.

The award for entrepreneurial performance worldwide is based on criteria such as growth, future potential, innovation, employee management and social responsibility.

"Rentschler Biopharma is a family-owned business that has been successful for five generations," commented Rentschler. "When looking back on the strong development and growth we have experienced over the past few years, I believe a key factor is the exceptionally good cooperation between Frank Mathias and myself. Our strong relationship is characterized by complete openness and mutual trust. Combining our shared passion and entrepreneurial spirit, we put a lot of thought into the necessary next steps to advance our business and continue to be a leader in our field. The 'Entrepreneur of the Year' Award is a terrific acknowledgement for us."

Mathias added: "Entrepreneurs often receive all of the recognition for a successful company; however, it is the dedicated contribution of our employees – the work of many minds, many hands and many hours – that is crucial to our success. Rentschler Biopharma has an exceptional team that is doing an excellent job to meet the needs of our clients in bioprocess development and manufacturing all over the world. I am proud of our team and extremely pleased to accept the 'Entrepreneur of the Year' Award on behalf of everyone at the company."

Company

Logo:

Rentschler Biopharma SE

Erwin-Rentschler-Str. 21
88471 Laupheim
Germany

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.